Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Daratumumab in RRMM
NCT03000452Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2017
- Primary completion
- Sep 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Objective Response Rate. Started Mar 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03000452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000452.